X0407 4/A 2022-09-16 2022-09-19 0 0001556263 Syros Pharmaceuticals, Inc. SYRS 0001207405 TYSON TIMOTHY 35 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140 1 0 0 0 0 Common Stock 2022-09-16 4 A 0 8000 0.00 A 8000 D Common Stock 2022-09-16 4 A 0 257 A 8257 D Stock Option (right to buy) 7.349 2022-09-16 4 A 0 12000 0.00 A 2032-09-15 Common Stock 12000 12000 D Stock Option (right to buy) 93.56 2022-09-16 4 A 0 2232 A 2022-11-21 Common Stock 2232 2232 D Stock Option (right to buy) 199.68 2022-09-16 4 A 0 1094 A 2026-05-09 Common Stock 1094 1094 D Stock Option (right to buy) 66.18 2022-09-16 4 A 0 3286 A 2028-05-24 Common Stock 3286 3286 D Stock Option (right to buy) 53.17 2022-09-16 4 A 0 2191 A 2028-08-26 Common Stock 2191 2191 D Stock Option (right to buy) 26.93 2022-09-16 4 A 0 2191 A 2029-08-22 Common Stock 2191 2191 D Stock Option (right to buy) 27.84 2022-09-16 4 A 0 2848 A 2030-08-19 Common Stock 2848 2848 D Stock Option (right to buy) 25.10 2022-09-16 4 A 0 3856 A 2031-08-23 Common Stock 3856 3856 D Stock Option (right to buy) 7.07 2022-09-16 4 A 0 3856 A 2032-08-23 Common Stock 3856 3856 D Acquired pursuant to the merger agreement between the issuer and Tyme Technologies, Inc. ("Tyme") in exchange for 5,865 shares of Tyme common stock having a market value of $0.3086 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares. The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022. This option is fully vested and replaced an option to purchase 50,058 shares of Tyme common stock at an exercise price of $4.10 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split. This option is fully vested and replaced an option to purchase 25,000 shares of Tyme common stock at an exercise price of $8.75 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split. This option is fully vested and replaced an option to purchase 75,000 shares of Tyme common stock at an exercise price of $2.90 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split. This option is fully vested and replaced an option to purchase 50,000 shares of Tyme common stock at an exercise price of $2.33 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split. This option is fully vested and replaced an option to purchase 50,000 shares of Tyme common stock at an exercise price of $1.18 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split. This option is fully vested and replaced an option to purchase 65,000 shares of Tyme common stock at an exercise price of $1.22 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split. This option is fully vested and replaced an option to purchase 88,000 shares of Tyme common stock at an exercise price of $1.10 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split. This option is fully vested and replaced an option to purchase 88,000 shares of Tyme common stock at an exercise price of $0.31 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split. This amendment to the Statement of Changes in Beneficial Ownership of Securities is being filed to correct the inadvertent omission of the Reporting Person's beneficial ownership of certain securities issued in connection with the closing of the merger with Tyme on September 16, 2022. /s/ Todd Rosenthal, as attorney-in-fact 2023-04-20